News & Updates
Filter by Specialty:
Empagliflozin lowers mortality, cardiorenal events even in COPD presence
Among patients with type 2 diabetes mellitus and cardiovascular disease, those with concomitant chronic obstructive pulmonary disease (COPD) are at higher risk of mortality and adverse cardiorenal outcomes, including heart failure, according to post hoc analyses of the EMPA-REG OUTCOME trial. However, these outcomes can be prevented with empagliflozin treatment, regardless of the presence of COPD.
Empagliflozin lowers mortality, cardiorenal events even in COPD presence
28 Mar 2022
TNFi use does not induce hypertension in ankylosing spondylitis
Use of tumour necrosis factor inhibitor (TNFi) does not appear to contribute to incident hypertension in individuals with ankylosing spondylitis (AS), reports a study.
TNFi use does not induce hypertension in ankylosing spondylitis
25 Mar 2022
Light drinking may protect against death after myocardial infarction
Following an episode of myocardial infarction (MI), patients with light or moderate alcohol consumption appear to have a lower risk of mortality than nondrinkers, according to a study.
Light drinking may protect against death after myocardial infarction
24 Mar 2022
Wall motion abnormalities up risk of heart failure
Global wall motion score index (WMSI), as well as abnormalities in any of the left ventricular (LV) regional walls, is associated with the risk of incident heart failure (HF), reports a new study.